Federal Register / Vol. 60, No. 2 / Wednesday, January 4, 1995 / Notices 471

contract proposals and for the critique

and evaluation of extramural/intramural

programmatic and personnel policies,

including consideration of personnel

qualifications and performance and the

competence of individual investigators.

These applications and proposals and

the discussions could reveal

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the

applications and proposals, the

disclosure of which would constitute a

clearly unwarranted invasion of

personal privacy.

Ms. Carole Frank, the Committee

Management Officer, National Cancer

Institute, Executive Plaza North, Room

630E, 6130 Executive Blvd MSC 7405,

Bethesda, Maryland 20892–7405, (301–

496–5708) will provide a summary of

the meetings and the roster of

committee members, upon request.

For other information pertaining to

the meetings or individuals who plan to

attend and need special assistance, such

as sign language interpretation or other

reasonable accommodations, contact the

contact person indicated below.

Committee Name: Board of Scientific

Counselors, Division of Cancer

Prevention and Control

Contact Person: Ms. Linda M.

Bremerman, Executive Plaza North,

Rm 232, Telephone: (301) 496–8526

Date of Meeting: January 19–20, 1995

Place of Meeting: Building 31,

Conference Room 10, 9000 Rockville

Pike, Bethesda, MD 20892

Open: January 19, 1995, 8:30 am to 12

pm, January 20, 10:15 am to

adjournment

Agenda: Review progress of programs

within the Division and review of

concepts being considered for

funding.

Closed: January 19, 1995, 3:15 pm to 5

pm

Agenda: Extramural/Intramural

programmatic and personnel policies

of a sensitive nature and

consideration of personnel

qualifications and performance and

the competence of individual

investigators.

Place of Meeting: Building 31,

Conference Room 9, 9000 Rockville

Pike, Bethesda, MD 20892

Open: January 19, 1995, 1 pm to 3 pm

Agenda: Discuss current and future

programs of the subcommittee and

review of concepts being considered

for funding.

Committee Name: Biometry and

Epidemiology Contract Review

Committee

Contact Person: Dr. Harvey P. Stein,

Room 601c, Executive Plaza North,

Telephone: (301) 496–7030

Date of Meeting: February 3, 1995

Place of Meeting: Conference Room G,

6130 Executive Boulevard, Rockville,

MD 20852

Closed: February 3, 1995, 9 am to

adjournment

Agenda: Review, discussion and

evaluation of individual contract

proposals.

Committee Name: Subcommittee A of

the Cancer Research Manpower and

Education Review Committee

Contact Person: Dr. Mary Bell, Room

611A, Executive Plaza North,

Telephone: (301) 496–7978

Date of Meeting: February 14–17, 1995

Place of Meeting: The Holiday Inn, 2101

Wisconsin Avenue, NW., Washington,

DC 20007

Closed:

February 14, 1995 7:30 pm to recess

February 15, 1995 8 am to recess

February 16, 1995 8 am to recess

February 17, 1995 8 am to adjournment

Agenda: Review, discussion and

evaluation of individual grant

applications.

(Catalog of Federal Domestic Assistance

Program Numbers: 93.393, Cancer Cause and

Prevention Research; 93.394, Cancer

Detection and Diagnosis Research; 93.395,

Cancer Treatment Research; 93.396, Cancer

Biology Research; 93.397, Cancer Centers

Support; 93.398, Cancer Research Manpower;

93.399, Cancer Control.)

Dated: December 27, 1994.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95–43 Filed 1–3–95; 8:45 am]

BILLING CODE 4140–01–M

National Heart, Lung, and Blood

Institute; Notice of Closed Meetings

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following Heart,

Lung, and Blood Special Emphasis

Panel (SEP) meetings:

Name of SEP: Innovative Ventricular Assist

System (IVAS)

Date: January 18–19, 1995

Time: 7:30 p.m.

Place: Residence Inn, Bethesda, Maryland

Contact Person: Carl A. Ohata, Ph.D., 5333

Westbard Avenue, Room 5A09, Bethesda,

Maryland 20892 (301) 594–7483

Purpose/Agenda: To evaluate and review

contract proposals.

Name of SEP: Clinical Center for Etiology of

Sarcoidosis: A Case Control Study—

Coordinating Center

Date: January 27, 1995

Time: 12:00 p.m.

Place: Holiday Inn, Chevy Chase, Maryland

Contact Person: S. Charles Selden, Ph.D.,

5333 Westbard Avenue, Room 552,

Bethesda, Maryland 20892 (301) 594–7476

Purpose/Agenda: To evaluate and review

contract proposals.

These meetings will be closed in

accordance with the provisions set forth

in sec. 552b(c)(4) and 552b(c)(6), Title 5,

U.S.C. Applications and/or proposals

and the discussions could reveal

confidential trade secrets or commercial

property such as patentable material

and personal information concerning

individuals associated with the

applications and/or proposals, the

disclosure of which would constitute a

clearly unwarranted invasion of

personal privacy.

(Catalog of Federal Domestic Assistance

Programs Nos. 93.837, Heart and Vascular

Diseases Research; 93.838 Lung Diseases

Research; and 93.839, Blood Diseases and

Resources Research, National Institutes of

Health.)

Dated: December 23, 1994.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95–44 Filed 1–3–95; 8:45 am]

BILLING CODE 4140–01–M

Public Health Service

Statement of Organizations, Functions,

and Delegations of Authority; Office of

the Assistant Secretary for Health

Part H, Public Health Service (PHS),

Chapter HA (Office of the Assistant

Secretary for Health), of the Statement

of Organization, Functions, and

Delegations of Authority for the

Department of Health Services (DHHS)

(42 FR 61318, December 2, 1977, as

amended most recently at 59 FR 52553–

52554, October, 18, 1994) is amended to

reflect changes in reporting

relationships in the Office of the

Assistant Secretary for Health.

Office of the Assistant Secretary for

Health

Under Chapter HA, Office of the

Assistant Secretary for Health, Section

HA–10, Organization, delete the list and

insert the following:

1. Office of Health Communications

(HAB)

2. President’s Council on Physical

Fitness and Sports (HAC)

3. Office of Research Integrity (HAG)

4. National AIDS Program Office (HAA)

5. Office of Health Legislation (HAJ)

6. Office of Equal Employment

Opportunity (HAK)

7. Office of International and Refugee

Health (HAL)

8. Office of Minority Health (HAM)

9. Office of the Surgeon General (HAN)
472 Federal Register / Vol. 60, No. 2 / Wednesday, January 4, 1995 / Notices

10. Office of Emergency Preparedness

(HAP)

11. Office of Management (HAU)

12. Office of Disease Prevention and

Health Promotion and Health

Planning and Evaluation (HAV)

13. Office on Women’s Health (HAW)

14. National Vaccine Program Office

(HA2)

15. Office of Population Affairs (HA5)

16. PHS Executive Secretariat (HA6)

17. Office of Intergovernmental Affairs

(HA7)

Under Chapter HA, Section HA–20,

Functions, in the statement for the

Office of Communications (HAB),

change the title to Office of Health

Communications (HAB), delete the first

sentence and insert the following:

The Office is under the direction of

the Deputy Assistant Secretary for

Health (Communications) who advises

the Assistant Secretary for Health,

through the Principal Deputy Assistant

Secretary for Health, on a PHS-wide

strategic communications program.

Following the title President’s Council

on Physical Fitness and Sports (HAC),

insert a new first sentence, as follows:

The President’s Council on Physical

Fitness and Sports is directed by the

Executive Director who reports to the

Principal Deputy Assistant Secretary for

Health.

Following the title Office of Equal

Employment Opportunity (HAK), delete

the first paragraph and insert the

following:

The Director, Office of Equal

Employment Opportunity (OEEO),

reports to the Principal Deputy

Assistant Secretary for Health on EEO

policy and on operational matters to the

Deputy Assistant Secretary for Health

(Management and Budget), who serves

as the Director of the PHS Equal

Employment Opportunity Program and

as the principal advisor on all PHS

equal employment matters. The

Director, OEEO, serves as Deputy

Director of the PHS Equal Employment

Opportunity Program to provide

functional supervision throughout PHS

and to direct OEEO activities.

In the statement for the Office of

Minority Health (HAM), delete the first

sentence and insert the following:

The Deputy Assistant Secretary for

Minority Health serves as the Director of

the Office of Minority Health and

advises the Assistant Secretary for

Health, through the Principal Deputy

Assistant Secretary for Health, about

health program activities that address

minority populations, develops policies

for the improvement of the health status

of minority populations, and

coordinates all PHS minority health

activities.

In the statement for the Office of

Emergency Preparedness (HAP), delete

the first phrase and insert the following:

The Director of the Office of

Emergency Preparedness: (1) Advises

the Assistant Secretary for Health,

through the Principal Deputy Assistant

Secretary for Health, on emergency

preparedness to:

Following the statement for the

Division of Payment Management

(HAU45), add the following:

Office of Disease Prevention and

Health Promotion and Health Planning

and Evaluation (HAV). The Deputy

Assistant Secretary for Health (Disease

Prevention and Health Promotion and

Health Planning and Evaluation) serves

as the Director of the Office and advises

the Assistant Secretary for Health,

through the Principal Deputy Assistant

Secretary for Health, on health policies,

procedures, and activities which relate

to disease prevention, health promotion,

preventive health services, health

information and education, and national

health planning and evaluation. The

Office provides a program of leadership,

coordination and liaison between PHS

and other Federal agencies, national

non-Federal organizations, State and

local agencies and private sector

organizations that have roles in disease

prevention, health promotion and

national health planning. The Office

coordinates the development of national

health policy, plans, legislative

proposals, regulations, and the conduct

of health policy analyses and

evaluations.

In the statement for the Office on

Women’s Health (HAW), delete the first

sentence and insert a new sentence, as

follows:

The Deputy Assistant Secretary for

Women’s Health, who reports to the

Principal Deputy Assistant Secretary for

Health, is Director of the Office on

Women’s Health and serves as advisor

on scientific, legal, ethical, and policy

issues relating to women’s health.

In the statement for the National

Vaccine Program Office (HA2), delete

the first sentence and insert the

following:

The Deputy Director of the National

Vaccine Program (NVP) serves as the

Director, National Vaccine Program

Office, and reports to the Assistance

Secretary for Health regarding NVP

activities and to the Principal Deputy

Assistant Secretary for Health on

operational and administrative matters.

Following the statement for the

National Vaccine Program Office (HA2),

delete the title and statement in their

entirety for the Senior Advisor for

Environmental Affairs (HA3).

In the statement for the Office of

Population Affairs (HA5) delete the first

paragraph and insert the following:

The Office is under the direction of

the Deputy Assistant Secretary for

Population Affairs who advises the

Assistant Secretary for Health regarding

the mandated provisions of Title X,

Population Research and Voluntary

Family Planning Programs; and Title

XX, Adolescent Family Life

Demonstration Projects and provisions

of Title XVII, Office of Adolescent

Health of the Public Health Service Act;

and who reports to the Principal Deputy

Assistant Secretary for Health

concerning other operational and

administrative matters.

Following the title PHS Executive

Secretariat (HA6), insert a new first

sentence, as follows:

The Director of the PHS Executive

Secretariat reports to the Principal

Deputy Assistant Secretary for Health.

In the statement for the Office of

Intergovernmental Affairs (HA7), delete

the beginning phrase and insert the

following:

The Director of the Office of

Intergovernmental Affairs reports to the

Principal Deputy Assistant Secretary for

Health. The Office:

After the statement for the Office of

Intergovernmental Affairs (HA7), delete

the titles and statements in their entirety

for the Office of Disease Prevention and

Health Promotion (HA8) and the Office

of Health Planning and Evaluation

(HA9).

Public Health Service (PHS) Regional

Offices

Under Chapter HD, Section HD–20

Functions, following the title Public

Health Service (PHS) Regional Office

(HD1–HDX), delete the first sentence

and insert the following:

The Public Health Service (PHS)

Regional Offices are headed by Regional

Health Administrators (RHA), who

report to the Principal Deputy Assistant

Secretary for Health and who serve as

regional PHS representatives. The RHA

directs and administers Regional Office

activities and is responsible for

integrating health and medical expertise

with regional program efforts.

Office of the Assistant Secretary for

Health

Under Chapter HD, Section HD–30,

Delegations of Authority, add the

following:

All delegations and redelegations of

authority to officers and employees of

the OASH which were in effect

immediately prior to the effective date

of this reorganization will be continued

in effect in them or their successors,
Federal Register / Vol. 60, No. 2 / Wednesday, January 4, 1995 / Notices 473

pending further redelegation, provided

they are consistent with this

reorganization.

Donna E. Shalala,

Secretary.

[FR Doc. 95–114 Filed 1–3–95; 8:45 am]

BILLING CODE 4160–17–M

Substance Abuse and Mental Health

Services Administration

Current List of Laboratories Which

Meet Minimum Standards To Engage in

Urine Drug Testing for Federal

Agencies and Laboratories That Have

Withdrawn From the Program

AGENCY: Substance Abuse and Mental

Health Services Administration, HHS

(Formerly: National Institute on Drug

Abuse, ADAMHA, HHS).

ACTION: Notice.

SUMMARY: The Department of Health and

Human Services notifies Federal

agencies of the laboratories currently

certified to meet standards of Subpart C

of Mandatory Guidelines for Federal

Workplace Drug Testing Programs (59

FR 29916, 29925). A similar notice

listing all currently certified laboratories

will be published during the first week

of each month, and updated to include

laboratories which subsequently apply

for and complete the certification

process. If any listed laboratory’s

certification is totally suspended or

revoked, the laboratory will be omitted

from updated lists until such time as it

is restored to full certification under the

Guidelines.

If any laboratory has withdrawn from

the National Laboratory Certification

Program during the past month, it will

be identified as such at the end of the

current list of certified laboratories, and

will be omitted from the monthly listing

thereafter.

FOR FURTHER INFORMATION CONTACT: Mrs.

Giselle Hersh, Division of Workplace

Programs, Room 13A–54, 5600 Fishers

Lane, Rockville, Maryland 20857; Tel.:

(301) 443–6014.

SUPPLEMENTARY INFORMATION:

Mandatory Guidelines for Federal

Workplace Drug Testing were developed

in accordance with Executive Order

12564 and section 503 of Pub. L. 100–

71. Subpart C of the Guidelines,

‘‘Certification of Laboratories Engaged

in Urine Drug Testing for Federal

Agencies,’’ sets strict standards which

laboratories must meet in order to

conduct urine drug testing for Federal

agencies. To become certified an

applicant laboratory must undergo three

rounds of performance testing plus an

on-site inspection. To maintain that

certification a laboratory must

participate in a quarterly performance

testing program plus periodic, on-site

inspections.

Laboratories which claim to be in the

applicant stage of certification are not to

be considered as meeting the minimum

requirements expressed in the HHS

Guidelines. A laboratory must have its

letter of certification from SAMHSA,

HHS (formerly: HHS/NIDA) which

attests that it has met minimum

standards.

In accordance with Subpart C of the

Guidelines, the following laboratories

meet the minimum standards set forth

in the Guidelines:

ACCU–LAB, Inc., 405 Alderson St.,

Schofield, WI 54476, 800–627–8200

(formerly: Alpha Medical Laboratory, Inc.,

Employee Health Assurance Group,

ExpressLab, Inc.)

Aegis Analytical Laboratories, Inc., 624

Grassmere Park Rd., Suite 21, Nashville,

TN 37211, 615–331–5300

Alabama Reference Laboratories, Inc., 543

South Hull St., Montgomery, AL 36103,

800–541–4931/205–263–5745

American Medical Laboratories, Inc., 14225

Newbrook Dr., Chantilly, VA 22021, 703–

802–6900

Associated Pathologists Laboratories, Inc.,

4230 South Burnham Ave., Suite 250, Las

Vegas, NV 89119–5412, 702–733–7866

Associated Regional and University

Pathologists, Inc. (ARUP), 500 Chipeta

Way, Salt Lake City, UT 84108, 801–583–

2787

Baptist Medical Center—Toxicology

Laboratory, 9601 I–630, Exit 7, Little Rock,

AR 72205–7299, 501–227–2783 (formerly:

Forensic Toxicology Laboratory Baptist

Medical Center)

Bayshore Clinical Laboratory, 4555 W.

Schroeder Dr., Brown Deer, WI 53223,

414–355–4444/800–877–7016

Cedars Medical Center, Department of

Pathology, 1400 Northwest 12th Ave.,

Miami, FL 33136, 305–325–5810

Center for Laboratory Services, a Division of

LabOne, Inc., 8915 Lenexa Dr., Overland

Park, Kansas 66214, 913–888–3927

Centinela Hospital Airport Toxicology

Laboratory, 9601 S. Sepulveda Blvd., Los

Angeles, CA 90045, 310–215–6020

Clinical Reference Lab, 11850 West 85th St.,

Lenexa, KS 66214, 800–445–6917

Cox Medical Centers, Department of

Toxicology, 1423 North Jefferson Ave.,

Springfield, MO 65802, 800–876–3652/

417–836–3093

Damon/MetPath, 8300 Esters Blvd., Suite

900, Irving, TX 75063, 214–929–0535

(formerly: Damon Clinical Laboratories)

Dept. of the Navy, Navy Drug Screening

Laboratory, Great Lakes, IL, Building 38–H,

Great Lakes, IL 60088–5223, 708–688–

2045/708–688–4171

Doctors Laboratory, Inc., P.O. Box 2658, 2906

Julia Dr., Valdosta, GA 31604, 912–244–

4468

Drug Labs of Texas, 15201 I–10 East, Suite

125, Channelview, TX 77530, 713–457–

3784

DrugProof, Division of Laboratory of

Pathology of Seattle, Inc., 1229 Madison

St., Suite 500, Nordstrom Medical Tower,

Seattle, WA 98104, 800–898–0180/206–

386–2672 (formerly: Laboratory of

Pathology of Seattle, Inc.)

DrugScan, Inc., P.O. Box 2969, 1119 Mearns

Rd., Warminster, PA 18974, 215–674–9310

Eagle Forensic Laboratory, Inc., 950 N.

Federal Highway, Suite 308, Pompano

Beach, FL 33062, 305–946–4324

ElSohly Laboratories, Inc., 5 Industrial Park

Dr., Oxford, MS 38655, 601–236–2609

General Medical Laboratories, 36 South

Brooks St., Madison, WI 53715, 608–267–

6267

Harrison Laboratories, Inc., 9930 W. Highway

80, Midland, TX 79706, 800–725–3784/

915–563–3300 (formerly: Harrison &

Associates Forensic Laboratories)

HealthCare/MetPath, 24451 Telegraph Rd.,

Southfield, MI 48034, Inside MI: 800–328–

4142 / Outside MI: 800–225–9414

(formerly: HealthCare/Preferred

Laboratories)

Holmes Regional Medical Center Toxicology

Laboratory, 5200 Babcock St., N.E., Suite

107, Palm Bay, FL 32905, 407–726–9920,

Jewish Hospital of Cincinnati, Inc., 3200

Burnet Ave., Cincinnati, OH 45229, 513–

569–2051

Laboratory Specialists, Inc., 113 Jarrell Dr.,

Belle Chasse, LA 70037, 504–392–7961

Marshfield Laboratories, 1000 North Oak

Ave., Marshfield, WI 54449, 715–389–

3734/800–222–5835

Med-Chek/Damon, 4900 Perry Hwy.,

Pittsburgh, PA 15229, 412–931–7200

(formerly: Med-Chek Laboratories, Inc.)

MedExpress/National Laboratory Center,

4022 Willow Lake Blvd., Memphis, TN

38175, 901–795–1515

Medical College Hospitals Toxicology

Laboratory, Department of Pathology, 3000

Arlington Ave., Toledo, OH 43699–0008,

419–381–5213

Medlab Clinical Testing, Inc., 212 Cherry

Lane, New Castle, DE 19720, 302–655–

5227

MedTox Laboratories, Inc., 402 W. County

Rd. D, St. Paul, MN 55112, 800–832–3244/

612–636–7466

Methodist Hospital of Indiana, Inc.,

Department of Pathology and Laboratory

Medicine, 1701 N. Senate Blvd.,

Indianapolis, IN 46202, 317–929–3587

Methodist Medical Center Toxicology

Laboratory, 221 N.E. Glen Oak Ave.,

Peoria, IL 61636, 800–752–1835/309–671–

5199

MetPath, Inc., 1355 Mittel Blvd., Wood Dale,

IL 60191, 708–595–3888

MetPath, Inc., One Malcolm Ave., Teterboro,

NJ 07608, 201–393–5000

Metropolitan Reference Laboratories, Inc.,

2320 Schuetz Rd., St. Louis, MO 63146,

800–288–7293

National Center for Forensic Science, 1901

Sulphur Spring Rd., Baltimore, MD 21227,

410–536–1485 (formerly: Maryland

Medical Laboratory, Inc.)

National Health Laboratories Incorporated,

2540 Empire Dr., Winston-Salem, NC

27103–6710, Outside NC: 919–760–4620/

800–334–8627 / Inside NC: 800–642–0894

National Health Laboratories Incorporated,

d.b.a. National Reference Laboratory,